Vivani Medical (NASDAQ:VANI – Get Free Report) and Heyu Biological Technology (OTCMKTS:HYBT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.
Earnings & Valuation
This table compares Vivani Medical and Heyu Biological Technology”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivani Medical | N/A | N/A | -$25.65 million | ($0.45) | -2.98 |
| Heyu Biological Technology | $80,000.00 | 451.71 | -$270,000.00 | N/A | N/A |
Heyu Biological Technology has higher revenue and earnings than Vivani Medical.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Vivani Medical | N/A | -102.42% | -49.21% |
| Heyu Biological Technology | -453.55% | -6.43% | -4.43% |
Analyst Recommendations
This is a summary of current ratings and price targets for Vivani Medical and Heyu Biological Technology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivani Medical | 0 | 0 | 1 | 0 | 3.00 |
| Heyu Biological Technology | 0 | 0 | 0 | 0 | 0.00 |
Vivani Medical presently has a consensus price target of $3.00, indicating a potential upside of 123.88%. Given Vivani Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Vivani Medical is more favorable than Heyu Biological Technology.
Institutional and Insider Ownership
6.8% of Vivani Medical shares are owned by institutional investors. 44.3% of Vivani Medical shares are owned by company insiders. Comparatively, 89.2% of Heyu Biological Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Vivani Medical has a beta of 3.2, meaning that its stock price is 220% more volatile than the S&P 500. Comparatively, Heyu Biological Technology has a beta of -17.74, meaning that its stock price is 1,874% less volatile than the S&P 500.
Summary
Vivani Medical beats Heyu Biological Technology on 6 of the 11 factors compared between the two stocks.
About Vivani Medical
Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.
About Heyu Biological Technology
Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.
Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.
